The lower levels of GLP-1 and GIP in the evening, could be an explanation for the often increased intake of food late in the evening
Large-scale cardiovascular outcome trials have demonstrated that certain GLP-1 agonists, including liraglutide, semaglutide, and dulaglutide, reduce the risk of major adverse cardiovascular events (MACE) such as myocardial infarction, stroke, and cardiovascular death in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors
Patients should verify that their pharmacy holds current state board of pharmacy licensure and, ideally, accreditation from the Pharmacy Compounding Accreditation Board (PCAB) or similar body
There is currently no cure for MS, but there are a variety of treatments available that can help manage symptoms, slow disease progression, and improve quality of life